The Potential Roles of RNA N6-Methyladenosine in Urological Tumors.

N6-methyladenosine (mA) is regarded as the most abundant, prevalent and conserved internal mRNA modification in mammalian cells. MA can be catalyzed by mA methyltransferases METTL3, METTL14 and WTAP (writers), reverted by demethylases ALKBH5 and FTO (erasers), and recognized by mA -binding proteins such as YTHDF1/2/3, IGF2BP1/2/3 and HNRNPA2B1 (readers). Emerging evidence suggests that mA modification is significant for regulating many biological and cellular processes and participates in the pathological development of various diseases, including tumors. This article reviews recent studies on the biological function of mA modification and the methylation modification of mA in urological tumors.